NCT03300570View on ClinicalTrials.gov

Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 27, 2018

Primary Completion Date

January 2, 2019

Study Completion Date

May 17, 2021

Conditions
Colorectal Carcinoma
Interventions
DRUG

Dolcanatide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

19107

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03300570 - Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers | Biotech Hunter | Biotech Hunter